L1077P CFTR pathogenic variant function rescue by Elexacaftor–Tezacaftor–Ivacaftor in cystic fibrosis patient-derived air–liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patients
Stefania Lo Cicero,Germana Castelli,Giovanna Blaconà,Sabina Maria Bruno,Giovanni Sette,Riccardo Pigliucci,Valeria Rachela Villella,Speranza Esposito,Immacolata Zollo,Francesca Spadaro,Ruggero De Maria,Mauro Biffoni,Giuseppe Cimino,Felice Amato,Marco Lucarelli,Adriana Eramo,Lo Cicero Stefania,Castelli Germana,Blaconà Giovanna,Bruno Sabina Maria,Sette Giovanni,Pigliucci Riccardo,Villella Valeria Rachela,Esposito Speranza,Zollo Immacolata,Spadaro Francesca,De Maria Ruggero,Biffoni Mauro,Cimino Giuseppe,Amato Felice,Lucarelli Marco,Eramo Adriana
DOI: https://doi.org/10.1186/s12931-023-02516-0
IF: 5.8
2023-09-09
Respiratory Research
Abstract:Cystic fibrosis (CF) is caused by defects of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CFTR-modulating drugs may overcome specific defects, such as the case of Trikafta, which is a clinically approved triple combination of Elexacaftor, Tezacaftor and Ivacaftor (ETI) that exhibited a strong ability to rescue the function of the most frequent F508del pathogenic variant even in genotypes with the mutated allele in single copy. Nevertheless, most rare genotypes lacking the F508del allele are still not eligible for targeted therapies. Via the innovative approach of using nasal conditionally reprogrammed cell (CRC) cell-based models that mimic patient disease in vitro , which are obtainable from each patient due to the 100% efficiency of the cell culture establishment, we theratyped orphan CFTR mutation L1077P. Protein studies, Forskolin-induced organoid swelling, and Ussing chamber assays congruently proved the L1077P variant function rescue by ETI. Notably, this rescue takes place even in the context of a single-copy L1077P allele, which appears to enhance its expression. Thus, the possibility of single-allele treatment also arises for rare genotypes, with an allele-specific modulation as part of the mechanism. Of note, besides providing indication of drug efficacy with respect to specific CFTR pathogenic variants or genotypes, this approach allows the evaluation of the response of single-patient cells within their genetic background. In this view, our studies support in vitro guided personalized CF therapies also for rare patients who are nearly excluded from clinical trials.
respiratory system